恒生创新药ETF（159316）上周“吸金”3.3亿元，最新规模近16亿元，创历史新高

Group 1 - The core indices related to the pharmaceutical sector showed positive performance, with the CSI Innovation Drug Industry Index and the CSI Biotechnology Theme Index both rising by 2.7%, while the CSI 300 Healthcare Index increased by 2.4% and the CSI Hong Kong Stock Connect Healthcare Comprehensive Index rose by 0.7%. However, the Hang Seng Hong Kong Stock Connect Innovation Drug Index experienced a slight decline of 0.1% [1] - The Hang Seng Innovation Drug ETF (159316) saw a net inflow of 330 million yuan last week, bringing its total size to 1.598 billion yuan, marking a historical high [1] Group 2 - The Hang Seng Innovation Drug Index focuses on leading innovative drug companies listed in Hong Kong, comprising no more than 40 stocks involved in innovative drug research, development, and production [2] - The Hang Seng Healthcare ETF tracks the CSI Hong Kong Stock Connect Healthcare Comprehensive Index, which includes 50 stocks from the healthcare sector, such as medical devices, biopharmaceuticals, and chemical drugs [2] - The CSI Innovation Drug Industry Index concentrates on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks primarily engaged in innovative drug research and development [2]